Interaction Checker

Wechselwirkungen von Nintedanib

Nintedanib (Ofev) hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 150 dokumentierte Wechselwirkungen: 0 schwerwiegende, 149 mittelschwere, 0 geringfügige und 1, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Mittelschwere Wechselwirkungen (149)

  • AcetylsalicylsäureNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Acetylsalicylsäure und DipyridamolThrombozytenaggregationshemmerMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • AmiodaronAntiarrhythmikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • ApixabanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • AprepitantCYP3A4-HemmerMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • ArgatrobanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • ArmodafinilZNS-StimulansMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Atazanavirantiretrovirales ArzneimittelMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Azelastin und FluticasonAntihistaminikumMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • BeclometasonKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • BetamethasonKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • BivalirudinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • BosentanCYP3A4-InduktorMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • BudesonidKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Budesonid und FormoterolKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Butalbital, Acetylsalicylsäure und KoffeinBarbituratMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Butalbital, Acetylsalicylsäure, Koffein und CodeinBarbituratMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • CarbamazepinAntiepileptikumMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • CelecoxibNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • CenobamatAntiepileptikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • CiclesonidKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • CiclosporinImmunsuppressivumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • CimetidinH2-BlockerMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • ClarithromycinMakrolid-AntibiotikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • ClobazamBenzodiazepinMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • ClobetasolKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • DabigatranAntikoagulans (Gerinnungshemmer)Mittelschwer

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Darunavirantiretrovirales ArzneimittelMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Darunavir und Cobicistatantiretrovirales ArzneimittelMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • DeferasiroxEisenpräparatMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • DeflazacortKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Desogestrel und Ethinylestradiolorales KontrazeptivumMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • DesonidKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • DexamethasonKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • DiclofenacNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Diclofenac und MisoprostolNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • DiflunisalNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • DiltiazemCalciumkanalblockerMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • DronedaronAntiarrhythmikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Drospirenon und Ethinylestradiolorales KontrazeptivumMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • EdoxabanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Efavirenzantiretrovirales ArzneimittelMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Efavirenz, Lamivudin und Tenofovirantiretrovirales ArzneimittelMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Elvitegravir, Cobicistat, Emtricitabin und Tenofovirantiretrovirales ArzneimittelMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • EnoxaparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • ErythromycinMakrolid-AntibiotikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • EslicarbazepinAntiepileptikumMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • EstradiolEstrogenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Estradiol und Dienogestorales KontrazeptivumMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Estradiol und NorethisteronEstrogenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • EtodolacNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Etonogestrel und EthinylestradiolEstrogenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Etravirinantiretrovirales ArzneimittelMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Etynodioldiacetat und Ethinylestradiolorales KontrazeptivumMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • EverolimusImmunsuppressivumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • FenoprofenNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • FluconazolAzol-AntimykotikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • FludrocortisonKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • FlunisolidKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • FluocinonidKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • FlurbiprofenNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • FluticasonKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Fluticason und SalmeterolKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • FondaparinuxAntikoagulans (Gerinnungshemmer)Mittelschwer

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Fosamprenavirantiretrovirales ArzneimittelMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • FosaprepitantCYP3A4-HemmerMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • FosphenytoinAntiepileptikumMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • FulvestrantEstrogenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • GriseofulvinAntimykotikumMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • HalobetasolKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • HeparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Hydrocodon und IbuprofenOpioidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • HydrocortisonKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • IbuprofenNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Ibuprofen und FamotidinNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • ImatinibCYP3A4-HemmerMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • IndometacinNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • IsoniazidAntibiotikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • ItraconazolAzol-AntimykotikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • IvacaftorCYP3A4-HemmerMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • KetoconazolAzol-AntimykotikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • KetoprofenNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • KetorolacNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Konjugierte EstrogeneEstrogenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Konjugierte Estrogene und BazedoxifenEstrogenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Lenacapavirantiretrovirales ArzneimittelMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • LevonorgestrelGestagenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Levonorgestrel und Ethinylestradiolorales KontrazeptivumMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • LoperamidQT-verlängerndes ArzneimittelMittelschwer

    Treat diarrhea at first signs with adequate hydration and antidiarrheal medication (e.g., loperamide), and consider dose reduction or treatment interruption if diarrhea continues [see Dosage and Administration (2.4) ]. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Lopinavir und Ritonavirantiretrovirales ArzneimittelMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • LorlatinibCYP3A4-InduktorMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • MedroxyprogesteronGestagenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • MefenaminsäureNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • MegestrolGestagenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • MeloxicamNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • MethylprednisolonKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • MifepristonCYP3A4-HemmerMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • MirabegronBeta-Adrenozeptor-AgonistMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • MitapivatCYP3A4-InduktorMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • MitotanCYP3A4-InduktorMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • ModafinilZNS-StimulansMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • MometasonKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • NabumetonNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • NafcillinPenicillin-AntibiotikumMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • NaproxenNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Naproxen und EsomeprazolNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • NefazodonAntidepressivumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Nevirapinantiretrovirales ArzneimittelMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Nirmatrelvir und RitonavirVirostatikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Norelgestromin und EthinylestradiolEstrogenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • NorethisteronGestagenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Norethisteron und Ethinylestradiolorales KontrazeptivumMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Norgestimat und Ethinylestradiolorales KontrazeptivumMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Norgestrel und Ethinylestradiolorales KontrazeptivumMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Olopatadin und MometasonAntihistaminikumMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Orphenadrin, Acetylsalicylsäure und KoffeinMuskelrelaxansMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • OxaprozinNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • OxcarbazepinAntiepileptikumMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • PalbociclibCYP3A4-HemmerMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Paracetamol und IbuprofenNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • PerampanelAntiepileptikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • PhenobarbitalBarbituratMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Phentermin und TopiramatZNS-StimulansMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • PhenytoinAntiepileptikumMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • PiroxicamNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • PosaconazolAzol-AntimykotikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • PrednisolonKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisonKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • PrimidonAntiepileptikumMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • ProgesteronGestagenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • RanolazinQT-verlängerndes ArzneimittelMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • RifabutinAntibiotikumMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • RifampicinAntibiotikumMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • RifapentinAntibiotikumMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Ritonavirantiretrovirales ArzneimittelMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • RivaroxabanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • SalsalatNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • SulindacNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Sumatriptan und NaproxenTriptanMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • SuvorexantSchlaf- und BeruhigungsmittelMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • SuzetriginCYP3A4-InduktorMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • TicagrelorThrombozytenaggregationshemmerMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • TolmetinNSARMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • TopiramatAntiepileptikumMittelschwer

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • TriamcinolonKortikosteroidMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • VerapamilCalciumkanalblockerMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • Veresterte Estrogene und MethyltestosteronEstrogenMittelschwer

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • VoriconazolAzol-AntimykotikumMittelschwer

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

  • WarfarinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

Keine relevante Wechselwirkung berichtet (1)

  • PirfenidonKeine Wechselwirkung

    Pirfenidone In a multiple-dose study conducted to assess the pharmacokinetic effects of concomitant treatment with nintedanib and pirfenidone, the coadministration of nintedanib with pirfenidone did not alter the exposure of either agent [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

Prüfen Sie Nintedanib gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.